Composition for reducing new-onset diabetes

Abstract

A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.

1 . A method of reducing an incidence of diabetes in a subject in need thereof, the method comprising administering to the subject a statin and a pharmaceutical composition containing at least one member selected from the group consisting of eicosapentaenoic acid and its pharmaceutically acceptable salts and esters, wherein the subject has a serum triglyceride concentration of at least 150 mg/dL. 
     
     
         2 . The method of  claim 1 , further comprising administering rosiglitazone to the subject. 
     
     
         3 . The method of  claim 1 , wherein the subject has hypertriglyceridemia. 
     
     
         4 . The method of  claim 1 , wherein the subject has a high risk of a diabetes incidence. 
     
     
         5 . The method of  claim 1 , wherein the subject has a serum total cholesterol level at least about 250 mg/dL. 
     
     
         6 . The method of  claim 1 , wherein the subject has a serum total cholesterol level about 250 mg/dL. 
     
     
         7 . The method of  claim 1 , wherein the subject has an LDL-C level of about 120 mg/dL. 
     
     
         8 . The method of  claim 1 , wherein the subject has a fasting blood glucose of less than 126 mg/dL. 
     
     
         9 . The method of  claim 1 , wherein the subject has a fasting blood glucose of at least 110 mg/dL and less than 126 mg/dL. 
     
     
         10 . The method of  claim 1 , wherein the subject has impaired glucose tolerance or obesity. 
     
     
         11 . The method of  claim 1 , wherein at least one member selected from the group consisting of eicosapentaenoic acid and its pharmaceutically acceptable salts and esters is ethyl eicosapentate or eicosapentaenoic acid. 
     
     
         12 . The method of  claim 1 , wherein the pharmaceutical composition comprises at least about 96.5%, by weight, at least one member selected from the group consisting of eicosapentaenoic acid and its pharmaceutically acceptable salts and esters of a total weight of fatty acids in the pharmaceutical composition. 
     
     
         13 . The method of  claim 1 , wherein the pharmaceutical composition is administered to the subject for at least about 2 years.